Company Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including β-amyloid, or Aβ and ɑ-synuclein which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Lisa Ricciardi |
Contact Details
Address: 2500 Westchester Ave. Purchase, New York 10577 United States | |
| Phone | 412 481 2210 |
| Website | cogrx.com |
Stock Details
| Ticker Symbol | CGTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 1455365 |
| CUSIP Number | 19243B102 |
| ISIN Number | US19243B1026 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lisa Ricciardi | Chief Executive Officer, President and Director |
| John Brendan Doyle | Chief Financial Officer |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer |
| Dr. Steven A. Weissman Ph.D. | Vice President and Head of CMC |
| Anita Cornet | Head of Quality |
| Bobby Horn | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2026 | 10-K | Annual Report |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 8-K | Current Report |
| Jan 27, 2026 | 8-K | Current Report |
| Dec 23, 2025 | EFFECT | Notice of Effectiveness |
| Dec 18, 2025 | 8-K | Current Report |